FDA
label_change
· 2021-09-17
FDA Approved: SEGLUROMET — Supplemental Application (Merck Sharp & Dohme LLC)
Summary
FDA approved a supplemental application for Segluromet (ertugliflozin and metformin HCl) submitted by Merck to update the product labeling.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for SEGLUROMET (ERTUGLIFLOZIN AND METFORMIN HYDROCHLORIDE)